Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


eISSN: 1643-3750

The Effects of Intravitreal Ranibizumab, Aflibercept or Dexamethasone Implant Injections on Intraocular Pressure Changes

Yucel Karakurt, Turgay Ucak, Gamze Taslı, Burcu Agcayazı, Erel İcel, Hayati Yılmaz

Department of Ophthalmology, Erzincan University, Faculty of Medicine, Erzincan, Turkey

Med Sci Monit 2018; 24:9019-9025

DOI: 10.12659/MSM.910923

Available online:

Published: 2018-12-13


BACKGROUND: The aim of this study was to compare the alterations in intraocular pressure (IOP) values during the early postoperative period after intravitreal ranibizumab, aflibercept, or dexamethasone implant injections.
MATERIAL AND METHODS: In this retrospective study, a total of 188 patients were grouped into 3 groups: the ranibizumab group, the aflibercept group, and the dexamethasone group. Ocular axial length (AXL) and anterior chamber depth (ACD) were measured in the pre-injection period. IOP was measured just before the injection at 1 minute,10 minutes, 1 hour, 1 day, and 1 month after injection.
RESULTS: There was a transient peak in the ranibizumab group and the aflibercept group at 1 minute that started to decrease at 10 minutes and IOP values returned to preoperative values at approximately 1 hour. Similar alterations were also determined for the dexamethasone group with a lesser increase noted. In the correlation analysis, only alterations in IOP levels at 1 minute were negatively correlated with preoperative AXL values. There was not any correlation between preoperative AXL or ACD values and IOP alterations at any other time points.
CONCLUSIONS: There was a sudden, transient increase in IOP values after intravitreal ranibizumab or aflibercept injections; which return to normal values in a short time without requirement of any medical treatments. This transient peak was determined to be negatively correlated with the preoperative AXL.

Keywords: Axial Length, Eye, Intraocular Pressure, Intravitreal Injections